tirzepatide brand name in india Yurpeak® - Tirzepatidetablet for weight loss Yurpeak® Unveiling the Tirzepatide Brand Name in India: Mounjaro and Yurpeak® Lead the Way

Yurpeaktirzepatide The landscape of diabetes management and weight loss in India has been significantly reshaped with the introduction of tirzepatide, a groundbreaking dual-action medication.Cipla to sell Eli Lilly's weight loss drug under new brand in ... For those seeking to understand the prevalent tirzepatide brand name in India, the primary names that emerge are Mounjaro and, more recently, Yurpeak®. This article delves into the specifics of these brands, their availability, and the underlying science, providing a comprehensive overview grounded in expert knowledge and verifiable information.

Understanding Tirzepatide: A Dual-GIP/GLP-1 Agonist

At its core, tirzepatide is the active ingredient that powers these new therapeutic options. Developed by Eli Lilly and Company, it functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This innovative mechanism mimics the action of natural hormones, leading to improved glycemic control in individuals with type 2 diabetes and facilitating significant weight loss. Unlike older medications that target only one of these pathways, tirzepatide offers a more comprehensive approach.

Mounjaro®: The Pioneer Brand

Mounjaro® (pronounced "mown-JAHR-OH") was the first prominent brand name under which tirzepatide was launched in India. Eli Lilly and Company initially introduced Mounjaro in March 2025. It gained traction rapidly, becoming India's second-bestselling branded drug by September of the same year and subsequently evolving into India's top-selling drug by value in October 2025. This remarkable sales performance underscores its efficacy and market acceptance.2025年3月20日—The American drugmaker will roll out tirzepatide, sold under the brand nameMounjaro, in single-dose vials after receiving the marketing ...

Mounjaro is approved and marketed for both type 2 diabetes management, alongside diet and exercise, and for weight loss applications2025年10月23日—Tirzepatide, a GIP/GLP-1 dual agonist is the active ingredient used in Lilly's blockbuster GIP/GLP-1 dual agonist brandsMounjaro and Zepbound.. It is administered via subcutaneous injections (under the skin) once weekly.Eli Lilly's Mounjaro Becomes India's Top-Selling Drug Various strengths are available, including Mounjaro 2.5mg Solution for Injection 0.5ml, which contains tirzepatide. The drug's popularity is evident, with reported sales figures suggesting a rapid rise to significant market share. For instance, Mounjaro reportedly hit Rs. 100 crore in monthly sales by October 2025, a testament to its swift adoptionCipla has the rights to distribute and promoteYurpeak®— the second brand of Lilly's tirzepatide in India, after Lilly received DCGI approval.. In terms of pricing, a 5mg Mounjaro Tirzepatide Solution was listed on IndiaMART for approximately ₹4,375 per vial.

Internationally, tirzepatide is also known by the brand name Zepbound for weight loss applicationsMounjaro Weight Loss in Delhi – Cost, Results & Doctor- .... While Mounjaro and Zepbound share the same active ingredient, tirzepatide, their primary indications have seen some distinction in different markets. In India, the focus has broadly encompassed both diabetes and weight management under the Mounjaro brand.

Yurpeak®: A New Entrant with Familiar Roots

More recently, Cipla has entered the tirzepatide market in India with its brand, Yurpeak®. Cipla secured the rights to distribute and promote Yurpeak®, which represents Lilly's tirzepatide under a new brand in India, following regulatory approval from the Central Drugs Standard Control Organisation (CDSCO). This development signifies an expansion of access to tirzepatide in the country.2025年10月24日—Eli Lilly initially launched Tirzepatide in India in March 2025 under the brand nameMounjaro. Since its launch, Mounjaro has gained substantial ... Yurpeak is described as a one-weekly injection. The agreement details that Lilly will manufacture the drug, and Cipla will handle its marketing under the Yurpeak brand.

Expert Endorsement and Regulatory Approvals

The introduction and availability of tirzepatide in India have been supported by approvals from key regulatory bodies. The CDSCO has played a crucial role, with meetings of its scientific expert committees, such as the one dated 06.Mounjaro (Tirzepatide) is currently used as a second-line diabetes medication similar to glucagon like peptides 1 (GLP-1) drugs and is administered once weekly ...11.Mounjaro vs Zepbound: Differences, Uses, Side Effects & ...2025, contributing to the drug's evaluation. Eli Lilly, as the originator, has navigated these processes to bring Mounjaro and, subsequently, partner with Cipla for Yurpeak®.Is India about to make Ozempic-like weight-loss drugs a ... This journey reflects a commitment to providing advanced treatment options for conditions like type 2 diabetes and obesity, areas where India faces significant health challenges.

Comparing Tirzepatide to Other Medications

Garnering significant attention, tirzepatide is often compared to other popular medications like Ozempic (semaglutide) and Rybelsus (semaglutide)Tirzepatide (Mounjaro): India's New Dual-Action Treatment .... While Ozempic and Rybelsus are GLP-1 receptor agonists, tirzepatide distinguishes itself with its dual GIP and GLP-1 agonismTirzepatide is marketed under the brand nameMounjaro. Conclusion. Tirzepatide represents a significant advancement in the management of type 2 diabetes, .... Studies and clinical evaluations suggest that tirzepatide, under brands like Mounjaro, may offer greater efficacy in both glycemic control and weight reduction compared to GLP-1 receptor agonists alone.Tirzepatide, also known by the brand nameMounjaro®, has recently been approved by NICE (National Institute for Health and Care Excellence) for the management ... For instance, discussions revolve around how Mounjaro compares to other weight loss drugs, often highlighting its dual-action advantage.India approves Tirzepatide – A diabetes and weight-loss drug

Availability and Considerations in India

The availability of tirzepatide in India is primarily through prescription. While queries about buying Mounjaro online exist, including on platforms like Apollo Pharmacy for specific formulations like Mounjaro 22025年4月16日—Mounjaro is the brand name for the drug tirzepatide. It's an injectable prescription medication administered once weekly. Initially approved for ....5mg Solution for Injection 0.2025年10月23日—Under the agreement, Lilly will manufacture the drug and Cipla will market it under the brand nameYurpeak... tirzepatide injection drug ...5ml, it is essential to adhere to medical guidance. The drug is intended for use under strict doctor supervision for individuals struggling with obesity or type 2 diabetes. The cost of these medications is a critical consideration, with figures like the Yurpeak Cipla price in India and Tirzepatide India price being subjects of interest for many potential users.

In conclusion, the tirzepatide brand name in India is predominantly Mounjaro, with Yurpeak® emerging as a significant new offering. Both brands, powered by the active ingredient tirzepatide, represent a significant advancement in the management of type 2 diabetes and obesity, offering a powerful new therapeutic option for patients across the country.Cipla to sell Eli Lilly's weight loss drug under new brand in ... As the market continues to evolve, understanding these brand names and their associated benefits is crucial for informed healthcare decisions.